KOMET-007, NCT05735184: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML |
|
|
| Recruiting | 1 | 212 | US | Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine | Kura Oncology, Inc. | Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma | 05/26 | 05/27 | | |
